A decade after SARS: Strategies for controlling emerging coronaviruses

Nature Reviews Microbiology

Volumn 11, Issue 12, 2013, Pages 836-848

  Graham, Rachel L ^a   Donaldson, Eric F ^a   Baric, Ralph S ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SUBUNIT VACCINE; VIRUS VECTOR;

CORONAVIRUS; CORONAVIRUS INFECTION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; VIROGENESIS; VIRUS IDENTIFICATION; VIRUS MORPHOGENESIS; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN; VIRUS TRANSMISSION;

COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG DISCOVERY; HUMANS; RECEPTORS, VIRUS; VIRAL TROPISM; VIRAL VACCINES;

CORONAVIRUS; SARS CORONAVIRUS;

EID: 84888011629     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3143     Document Type: Review

References (152)

1. Zhong, N. Management and prevention of SARS in China. Phil. Trans. R. Soc. Lond. B Biol. Sci. 359, 1115-1116 (2004). (Pubitemid 38947036)
2. Peiris, J. S., Guan, Y. & Yuen, K. Y. Severe acute respiratory syndrome. Nature Med. 10, S88-S97 (2004). (Pubitemid 40018232)
3. Cherry, J. D. The chronology of the 2002-2003 SARS mini pandemic. Paediatr. Respir. Rev. 5, 262-269 (2004). (Pubitemid 39462668)
4. Anthony, S. J. et al. Coronaviruses in bats from Mexico. J. Gen. Virol. 94, 1028-1038 (2013).
5. Woo, P. C. et al. Discovery of seven novel mammalian and avian coronaviruses in the genus Deltacoronavirus supports bat coronaviruses as the gene source of Alphacoronavirus and Betacoronavirus and avian coronaviruses as the gene source of Gammacoronavirus and Deltacoronavirus. J. Virol. 86, 3995-4008 (2012)
6. Lau, S. K. et al. Recent transmission of a novel Alphacoronavirus, bat coronavirus HKU10, from Leschenault's rousettes to pomona leaf-nosed bats: first evidence of interspecies transmission of coronavirus between bats of different suborders. J. Virol. 86, 11906-11918 (2012).
7. Pfefferle, S. et al. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg. Infect. Dis. 15, 1377-1384 (2009).
8. Chu, D. K., Peiris, J. S., Chen, H., Guan, Y. & Poon, L. L. Genomic characterizations of bat coronaviruses (1A, 1B and HKU8) and evidence for co-infections in Miniopterus bats. J. Gen. Virol. 89, 1282-1287 (2008).
9. Woo, P. C. et al. Molecular diversity of coronaviruses in bats. Virology 351, 180-187 (2006). (Pubitemid 44037655)
10. Tang, X. C. et al. Prevalence and genetic diversity of coronaviruses in bats from China. J. Virol. 80, 7481-7490 (2006). (Pubitemid 44092570)
11. Lau, S. K. et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J. Clin. Microbiol. 44, 2063-2071 (2006). (Pubitemid 43902154)
12. Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676-679 (2005). (Pubitemid 41528160)
13. Lau, S. K. et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad. Sci. USA 102, 14040-14045 (2005) (Pubitemid 41377699)
14. Lu, L., Liu, Q., Du, L. & Jiang, S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 15, 625-629 (2013).
15. Annan, A. et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg. Infect. Dis. 19, 456-459 (2013).
16. Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. & Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814-1820 (2012)
17. van Boheemen, S. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3 e00473-12 (2012).
18. Chan, J. F. et al. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J. Infect. 65, 477-489 (2012).
19. Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201-12215 (2011).
20. Pyrc, K., Berkhout, B. & van der Hoek, L. Identification of new human coronaviruses. Expert Rev. Anti Infect. Ther. 5, 245-253 (2007). (Pubitemid 46681743)
21. Reed, S. E. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains. J. Med. Virol. 13, 179-192 (1984). (Pubitemid 14152575)
22. Peiris, J. S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319-1325 (2003) (Pubitemid 36514862)
23. Shi, Z. & Hu, Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 133, 74-87 (2008). (Pubitemid 351374754)
24. Li, W. et al. Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J. Virol. 80, 4211-4219 (2006).
25. Guan, Y. et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276-278 (2003). (Pubitemid 37248756)
26. Woo, P. C. et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884-895 (2005). (Pubitemid 40053872)
27. van der Hoek, L. et al. Identification of a new human coronavirus. Nature Med. 10, 368-373 (2004). (Pubitemid 38508514)
28. Fouchier, R. A. et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl Acad. Sci. USA 101, 6212-6216 (2004). (Pubitemid 38520553)
29. Talbot, H. K. et al. Coronavirus infection and hospitalizations for acute respiratory illness in young children. J. Med. Virol. 81, 853-856 (2009).
30. Wertheim, J. O., Chu, D. K., Peiris, J. S., Kosakovsky Pond, S. L. & Poon, L. L. A case for the ancient origin of coronaviruses. J. Virol. 87, 7039-7045 (2013).
31. Huynh, J. et al. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J. Virol. 86, 12816-12825 (2012).
32. Memish, Z. A., Zumla, A. I., Al-Hakeem, R. F., Al-Rabeeah, A. A. & Stephens, G. M. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 368, 2487-2494 (2013).
33. Assiri, A. et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369, 407-416 (2013).
34. Assiri, A. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752-761 (2013).
35. Reusken, C. B. et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13, 859-866 (2013).
36. Wang, N. et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23, 986-993 (2013)
37. Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 (2013)
38. Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454 (2003) (Pubitemid 37490132)
39. Kindler, E. et al. Efficient replication of the novel human Betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 4, e00611-00612 (2013).
40. Haagmans, B. L. et al. Pegylated interferon-? protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Med. 10, 290-293 (2004). (Pubitemid 38667620)
41. Chow, K. C., Hsiao, C. H., Lin, T. Y., Chen, C. L. & Chiou, S. H. Detection of severe acute respiratory syndrome-associated coronavirus in pneumocytes of the lung. Am. J. Clin. Pathol. 121, 574-580 (2004).
42. Guery, B. et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 381, 2265-2272 (2013).
43. Cotten, M. et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet http://dx.doi.org/10.1016/S0140-6736(13)61887-5 (2013).
44. Kan, B. et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J. Virol. 79, 11892-11900 (2005). (Pubitemid 41279306)
45. Song, H. D. et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl Acad. Sci. USA 102, 2430-2435 (2005).
46. Yu, S. et al. Retrospective serological investigation of severe acute respiratory syndrome coronavirus antibodies in recruits from mainland China. Clin. Diagn. Lab. Immunol. 12, 552-554 (2005). (Pubitemid 41175326)
47. Zheng, B. J. et al. SARS-related virus predating SARS outbreak, Hong Kong. Emerg. Infect. Dis. 10, 176-178 (2004). (Pubitemid 38176951)
48. Smith, I. & Wang, L. F. Bats and their virome: an important source of emerging viruses capable of infecting humans. Curr. Opin. Virol. 3, 84-91 (2013).
49. Wang, L. F. et al. Review of bats and SARS. Emerg. Infect. Dis. 12, 1834-1840 (2006).
50. Plowright, R. K. et al. Urban habituation, ecological connectivity and epidemic dampening: the emergence of Hendra virus from flying foxes (Pteropus spp.). Proc. Biol. Sci. 278, 3703-3712 (2011).
51. Becker, M. M. et al. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc. Natl Acad. Sci. USA 105, 19944-19949 (2008)
52. Carrington, C. V. et al. Detection and phylogenetic analysis of group 1 coronaviruses in South American bats. Emerg. Infect. Dis. 14, 1890-1893 (2008).
53. Vijgen, L. et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J. Virol. 79, 1595-1604 (2005). (Pubitemid 40459106)
54. Lau, S. K. et al. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of Pipistrellus bat coronavirus HKU5 in Japanese Pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J. Virol. 87, 8638-8650 (2013).
55. Muller, M. A. et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 3, e00515-12 (2012).
56. Munster, V. J., de Wit, E. & Feldmann, H. Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 368, 1560-1562 (2013).
57. Frieman, M. et al. Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease. J. Virol. 86, 884-897 (2012).
58. Day, C. W. et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395, 210-222 (2009).
59. Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3, e5 (2007)
60. Zhao, J., Zhao, J., Legge, K. & Perlman, S. Age-related increases in PGD2 expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J. Clin. Invest. 121, 4921-4930 (2011).
61. Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318-9325 (2010).
62. Zhao, J., Zhao, J., Van Rooijen, N. & Perlman, S. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 5, e1000636 (2009).
63. Sheahan, T. et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog. 4, e1000240 (2008).
64. Chen, W. et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. J. Med. Microbiol. 53, 435-438 (2004). (Pubitemid 38586511)
65. Li, C. K. et al. T cell responses to whole SARS coronavirus in humans. J. Immunol. 181, 5490-5500 (2008).
66. Roberts, A. et al. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J. Virol. 79, 5833-5838 (2005). (Pubitemid 40548251)
67. Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78, 3572-3577 (2004). (Pubitemid 38568299)
68. Hogan, R. J. et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J. Virol. 78, 11416-11421 (2004). (Pubitemid 39299685)
69. Glass, W. G., Subbarao, K., Murphy, B. & Murphy, P. M. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol. 173, 4030-4039 (2004). (Pubitemid 39280767)
70. Frieman, M. B. et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 6, e1000849 (2010).
71. Graham, R. L. et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nature Med. 18, 1820-1826 (2012).
72. Schaecher, S. R. et al. An immunosuppressed Syrian golden hamster model for SARS-CoV infection. Virology 380, 312-321 (2008).
73. Luo, D. et al. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing Fab?2. Viral Immunol. 20, 495-502 (2007). (Pubitemid 47585321)
74. Subbarao, K. & Roberts, A. Is there an ideal animal model for SARS? Trends Microbiol. 14, 299-303 (2006). (Pubitemid 43963366)
75. Roberts, A. et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J. Virol. 79, 503-511 (2005). (Pubitemid 39648403)
76. ter Meulen, J. et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363, 2139-2141 (2004). (Pubitemid 38844157)
77. Martina, B. E. et al. Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003). (Pubitemid 37376916)
78. Roper, R. L. & Rehm, K. E. SARS vaccines: where are we? Expert Rev. Vaccines 8, 887-898 (2009).
79. See, R. H. et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J. Gen. Virol. 89, 2136-2146 (2008).
80. Nagata, N. et al. Participation of both host and virus factors in induction of severe acute respiratory syndrome (SARS) in F344 rats infected with SARS coronavirus. J. Virol. 81, 1848-1857 (2007). (Pubitemid 46214457)
81. Fukushi, S. et al. Amino acid substitutions in the s2 region enhance severe acute respiratory syndrome coronavirus infectivity in rat angiotensin-converting enzyme 2-expressing cells. J. Virol. 81, 10831-10834 (2007). (Pubitemid 47463357)
82. Rockx, B. et al. Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PLoS ONE 6, e18558 (2011).
83. Greenough, T. C. et al. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am. J. Pathol. 167, 455-463 (2005). (Pubitemid 43026101)
84. McAuliffe, J. et al. Replication of SARS coronavirus administered into the respiratory tract of African green, rhesus and cynomolgus monkeys. Virology 330, 8-15 (2004). (Pubitemid 39446562)
85. Kuiken, T. et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263-270 (2003) (Pubitemid 36936836)
86. Smits, S. L. et al. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. J. Virol. 85, 4234-4245 (2011).
87. Falzarano, D. et al. Treatment with interferon-?2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nature Med. 19, 1313-1317 (2013).
88. Adedeji, A. O. et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J. Virol. 87, 8017-8028 (2013).
89. Breban, R., Riou, J. & Fontanet, A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382, 694-699 (2013).
90. Qu, D. et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 23, 924-931 (2005). (Pubitemid 39643181)
91. Takasuka, N. et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16, 1423-1430 (2004). (Pubitemid 39341555)
92. He, Y., Zhou, Y., Siddiqui, P. & Jiang, S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325, 445-452 (2004). (Pubitemid 39458016)
93. Enjuanes, L. et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 133, 45-62 (2008). (Pubitemid 351384650)
94. See, R. H. et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 87, 641-650 (2006).
95. Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).
96. Ishioka, T. et al. Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549). Cell Biol. Int. 35, 467-474 (2011).
97. Lin, J. T. et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 12, 1107-1113 (2007).
98. Vignuzzi, M., Wendt, E. & Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nature Med. 14, 154-161 (2008). (Pubitemid 351214560)
99. DeDiego, M. L. et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J. Virol. 81, 1701-1713 (2007).
100. Netland, J. et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399, 120-128 (2010).
101. Fett, C., DeDiego, M. L., Regla-Nava, J. A., Enjuanes, L. & Perlman, S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 87, 6551-6559 (2013).
102. Minskaia, E. et al. Discovery of an RNA virus 35 exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc. Natl Acad. Sci. USA 103, 5108-5113 (2006).
103. Eckerle, L. D. et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 6, e1000896 (2010).
104. Yount, B., Roberts, R. S., Lindesmith, L. & Baric, R. S. Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. Proc. Natl Acad. Sci. USA 103, 12546-12551 (2006). (Pubitemid 44267295)
105. Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA (2013)
106. Almazan, F. et al. Engineering a replication-competent, propagation-defective middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 4, e00650-13 (2013).
107. Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).
108. Baric, R. S. et al. SARS coronavirus vaccine development. Adv. Exp. Med. Biol. 581, 553-560 (2006).
109. Chen, Z. et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79, 2678-2688 (2005). (Pubitemid 40270546)
110. Bisht, H. et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl Acad. Sci. USA 101, 6641-6646 (2004). (Pubitemid 38586027)
111. Bukreyev, A. et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122-2127 (2004). (Pubitemid 38844152)
112. Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA 101, 9804-9809 (2004). (Pubitemid 38869317)
113. Faber, M. et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol. 86, 1435-1440 (2005). (Pubitemid 40613261)
114. Kapadia, S. U. et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340, 174-182 (2005). (Pubitemid 41317492)
115. Du, L. et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939-9942 (2013).
116. Li, F., Li, W., Farzan, M. & Harrison, S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864-1868 (2005) (Pubitemid 41325098)
117. Bisht, H., Roberts, A., Vogel, L., Subbarao, K. & Moss, B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 334, 160-165 (2005). (Pubitemid 40386951)
118. Liu, S. J. et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 24, 3100-3108 (2006).
119. Gupta, V. et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology 347, 127-139 (2006).
120. Woo, P. C. et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23, 4959-4968 (2005). (Pubitemid 41267024)
121. Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561-564 (2004).
122. Zakhartchouk, A. N., Liu, Q., Petric, M. & Babiuk, L. A. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23, 4385-4391 (2005). (Pubitemid 40991225)
123. Zhao, P. et al. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 331, 128-135 (2005). (Pubitemid 39593638)
124. Rockx, B. et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis. 201, 946-955 (2010).
125. Anthony, S. J. et al. A strategy to estimate unknown viral diversity in mammals. mBio 4, e00598-13 (2013).
126. Pensaert, M. B. & de Bouck, P. A new coronavirus-like particle associated with diarrhea in swine. Arch. Virol. 58, 243-247 (1978). (Pubitemid 9047249)
127. Snodgrass, D. R. et al. Aetiology of diarrhoea in young calves. Vet. Rec. 119, 31-34 (1986).
128. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003) (Pubitemid 36569984)
129. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003). (Pubitemid 36569985)
130. Narayanan, K., Huang, C. & Makino, S. SARS coronavirus accessory proteins. Virus Res. 133, 113-121 (2008). (Pubitemid 351374757)
131. Snijder, E. J. et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331, 991-1004 (2003). (Pubitemid 36969960)
132. Hofmann, H. et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl Acad. Sci. USA 102, 7988-7993 (2005). (Pubitemid 40781050)
133. Perlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. Nature Rev. Microbiol. 7, 439-450 (2009).
134. Pacciarini, F. et al. Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. J. Virol. 82, 5137-5144 (2008). (Pubitemid 351705222)
135. Vijgen, L. et al. Evolutionary history of the closely related group 2 coronaviruses: porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, and human coronavirus OC43. J. Virol. 80, 7270-7274 (2006). (Pubitemid 44025224)
136. Louz, D., Bergmans, H. E., Loos, B. P. & Hoeben, R. C. Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines. J. Gene Med. 7, 1263-1274 (2005). (Pubitemid 41555433)
137. Baric, R. S., Sullivan, E., Hensley, L., Yount, B. & Chen, W. Persistent infection promotes cross-species transmissibility of mouse hepatitis virus. J. Virol. 73, 638-649 (1999). (Pubitemid 28565408)
138. Glowacka, I. et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 85, 4122-4134 (2011).
139. Bertram, S. et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J. Virol. 85, 13363-13372 (2011).
140. Drosten, C. et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect. Dis. 13, 745-751 (2013).
141. Luyt, C. E., Combes, A., Trouillet, J. L., Nieszkowska, A. & Chastre, J. Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome. Presse Med. 40, e561-568 (2011).
142. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235-249 (2008). (Pubitemid 351512299)
143. Ware, L. B. & Matthay, M. A. The acute respiratory distress syndrome. N. Engl. J. Med. 342, 1334-1349 (2000). (Pubitemid 30408719)
144. Cameron, M. J. et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 81, 8692-8706 (2007). (Pubitemid 47242843)
145. Tang, N. L. et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin. Chem. 51, 2333-2340 (2005). (Pubitemid 41692578)
146. Reghunathan, R. et al. Expression profile of immune response genes in patients with Severe Acute Respiratory syndrome. BMC Immunol. 6, 2 (2005).
147. Jiang, Y. et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 171, 850-857 (2005). (Pubitemid 40575712)
148. Tsushima, K. et al. Acute lung injury review. Intern. Med. 48, 621-630 (2009).
149. Li, T. S. et al. Long-term outcome of acute respiratory distress syndrome caused by severe acute respiratory syndrome (SARS): an observational study. Crit. Care Resusc. 8, 302-308 (2006).
150. Gralinski, L. E. et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 4, e00271-13 (2013).
151. Graham, R. L. & Baric, R. S. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J. Virol. 84, 3134-3146 (2010).
152. Ge, X.-Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature http://dx.doi.org/10.1038/ nature12711 (2013).